Study of a new RNA drug for PNH anemia
Part of Blood & lymphatic clinical trials.
This trial tests an experimental RNA drug (ALN-CFB) for people with PNH who still have low red blood cell counts despite taking a C5 inhibitor. The drug aims to block a protein (complement factor B) to improve anemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with PNH (a rare blood disorder that destroys red blood cells).
- You have been on a stable dose of a C5 inhibitor (like eculizumab or ravulizumab) for at least 6 months.
- Your hemoglobin level is 10.5 g/dL or lower, meaning you have ongoing anemia.
- Your reticulocyte count (young red blood cells) is 100 or higher, showing your body is trying to make new cells.
- You have not had a bone marrow or organ transplant, and you do not have active infections or recent serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells are destroyed. If you have moderate anemia and high LDH (a marker of blood cell breakdown), this study may be an option.
This trial tests a new drug called SLN12140 for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not received complement inhibitor therapy. It aims to see if the drug can help control PNH symptoms.
This early-stage study tests how safe and tolerable ADX-038 is, and how the body processes it, in healthy volunteers and in people with paroxysmal nocturnal hemoglobinuria (PNH). It may help researchers understand whether the drug works safely for PNH patients and identify the right dosing.
This trial tests pegcetacoplan in children (ages 12–17) with paroxysmal nocturnal hemoglobinuria (PNH), a condition that can cause ongoing blood cell breakdown. The goal is to see if the medicine can improve anemia related to PNH.
This study tests an investigational oral medication called TUL321 in healthy volunteers to see if it is safe and how the body handles it. It may help understand the drug's effects and is an early step in developing a new treatment.
This study tests a new medicine called lanoracopan for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes red blood cells to break down too early. The medicine aims to control the disease and improve blood counts, potentially reducing anemia and other symptoms.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria (PNH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.